Answers are grounded in this paper and cite their sources.
A key aim of serosurveillance during the coronavirus disease 2019 (COVID-19) pandemic has been to estimate the prevalence of prior infection, by correcting crude seroprevalence against estimated test performance for polymerase chain reaction (PCR)-confirmed COVID-19. We show that poor generalizability of sensitivity estimates to some target populations may lead to substantial underestimation of case numbers.
No takes yet. Share an insight, caveat, or question.
Bailie et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: